Dalrada Financial Corp.
0.0360+0.01 (+28.6%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · DFCO · USD
Key Stats
Market Cap
4.33MP/E (TTM)
-Basic EPS (TTM)
-0.23Dividend Yield
0%Recent Filings
10-K
FY2025 results
Dalrada Financial Corporation posted FY2025 revenue of $20.3M, edging up 2.3% y/y from $19.8M, but net loss narrowed to $24.7M from $29.2M amid cost centralization, though a $2.7M goodwill impairment in Precision Manufacturing dragged results. Genefic revenue dipped 21.1% y/y to $10.4M on a pharmacy model shift, yet Climate Technology surged 188% to $8.1M fueled by construction gains, while Precision cratered 81.7% to $0.4M after losing a key client. Q4 momentum faltered with ongoing DepTec project delays and heat pump commercialization hurdles, but Bothof Brothers' contracts and pharmacy ramp-up hint at stabilization. Cash burned $18.0M in operations, offset by $18.8M in financing, leaving $0.5M on hand amid $8.9M debt; no dividends or buybacks occurred. No annual guidance disclosed. Ongoing litigation risks could further erode quarterly cash flows.
10-Q
Q3 FY2025 results
Dalrada Financial's Q3 FY2025 revenues climbed 33.5% y/y to $4.6M, fueled by a 528% surge in Dalrada Climate Technology from Bothof Brothers' construction wins, though Genefic dipped 40% on softer pharmacy sales. Gross profit swung to $1.4M from a $1.7M loss, lifting margins to 31%, yet operating expenses held steady at $5.3M, driving a $3.9M operating loss—better than last year's $8.7M hole. Net loss narrowed to $4.2M or $(0.05) per diluted share on 92.9M shares, with the gap to operating loss tied to $298K interest expense. Cash dwindled to $99K amid $6.1M operating burn, offset by $6.2M financing inflows including related-party notes; free cash flow not disclosed in the 10-Q. Acquired Grand Entrances in August 2024 for $100 cash plus $211K contingent consideration, adding $185K goodwill to integrate doors into construction. Liquidity strains persist with a $15.5M working capital deficit and going concern doubts. Ongoing litigation risks, like the Asset Group mask dispute, could drain resources further.
10-Q
Q2 FY2025 results
Dalrada Financial's Q2 FY2025 revenues fell 28.5% y/y to $3.1M, driven by a 38.6% drop in Genefic's pharmacy sales amid working capital constraints, yet Dalrada Climate Technology surged 67.5% y/y to $1.1M on stronger construction projects. Gross profit climbed 87.3% y/y to $835K, lifting margins to 26.8% from 10.2%, while operating loss narrowed 12.6% y/y to $5.1M. Net loss eased to $6.7M ($0.07 per diluted share) from $7.0M ($0.08), with the gap to operating loss tied to $1.0M interest expense and $748K other costs. Cash dwindled to $140K, offset by $4.5M financing inflows mainly from related-party notes, pushing total debt to $8.1M; free cash flow not disclosed in the 10-Q. Acquired Grand Entrances in August 2024 for $100 cash plus $211K contingent consideration, adding $185K goodwill to integrate with construction pipelines. Ongoing litigation risks, like the Asset Group mask contract dispute, could strain resources further. Losses persist.
10-Q
Q1 FY2025 results
Dalrada Financial's Q1 FY2025 revenues climbed 20% year-over-year to $6.0M, fueled by a 141% surge in Genefic's specialty and infusion pharmacy sales to $4.5M, though climate technology dipped 26% to $0.9M amid stalled Likido unit sales. Gross profit edged up 20% to $1.2M, but operating losses widened to $5.7M from $5.1M last year, driven by higher selling, general, and administrative costs including $1.0M in stock-based compensation. Net loss ballooned to $6.8M or $(0.07) per diluted share on 92.1M shares, versus $4.8M or $(0.05) prior year, with the gap largely from $1.1M interest expense on expanded debt. Cash dipped to $366K after $1.4M operating burn, offset by $1.9M financing inflows; total debt hit $8.1M while free cash flow wasn't disclosed in the 10-Q. In August 2024, the firm closed the $211K Grand Entrances acquisition for $100 cash plus contingent earnout, adding $185K goodwill to integrate doors into Bothof Brothers' construction. Yet liquidity strains persist.
8-K
Dalrada demoted to Expert Market
Dalrada Financial Corporation's OTC Markets status shifted to the Expert Market on January 15, 2025, triggered by its delayed Form 10-K filing for the fiscal year ended June 30, 2024. The delay stemmed from a mid-process auditor change, leaving the initial filing without a PCAOB-registered audit report despite meeting alternative standards. The company intends to file an amended 10-K soon, detailing any variances. This delisting hampers liquidity for investors.
CRAI
CRA International,Inc.
178.20-4.64
DAIC
CID HoldCo, Inc.
2.60-0.11
DGNX
Diginex Limited
15.80+0.90
FCN
FTI Consulting, Inc.
168.78-1.29
HURN
Huron Consulting Group Inc.
169.61+17.13
HYDTF
Hydreight Technologies Inc
3.28-0.09
ICFI
ICF International, Inc.
85.59-2.55
ROMA
Roma Green Finance Limited
2.65-0.21
SBC
SBC Medical Group Holdings Inco
3.38-0.28
ZGM
Zenta Group Company Limited
2.92-0.35